Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and …